| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Saikosaponin E targets key proteins involved in cancer and inflammation, including STAT3, IL-2, and PPP2CA as identified through network pharmacology analysis. It also modulates pathways associated with inflammatory cytokine production and viral replication.
|
|---|---|
| ln Vitro |
Saikosaponin E shows cytotoxicity against various human cell lines including A549, HepG2, Hep3B, Bcap37, and MCF7, with IC₅₀ values ranging from 15,420 nM to 21,290 nM. It exhibits strong antiviral activity against Influenza virus A/WSN/33(H1N1), achieving a 99.0% inhibition rate at 20 μM with an EC₅₀ of 2,140 nM. Cytotoxicity against human 293T cells shows a CC₅₀ of 2,850 nM with a selectivity index of 1.33.
|
| ln Vivo |
In vivo studies demonstrate protective effects against lipopolysaccharide-induced endometritis in mice, with evaluation of pathological changes and myeloperoxidase activity in uterine tissues via H&E staining and MPO detection kits. Inflammatory cytokines such as TNF-α are assessed to determine the compound's anti-inflammatory efficacy in animal models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays typically involve incubating saikosaponin E with target proteins or receptors in cell-free systems, followed by detection using fluorescence polarization, surface plasmon resonance, or ELISA-based binding measurements to determine affinity constants (Kd or IC₅₀).
|
| Cell Assay |
In vitro cell-based assays use human cancer cell lines (A549, HepG2, MCF7) cultured in appropriate media and treated with varying concentrations of saikosaponin E for 48-72 hours. Cell viability is assessed using MTT or CCK-8 assays to determine IC₅₀ values. Antiviral activity is evaluated in virus-infected cell cultures with plaque reduction or cytopathic effect inhibition assays.
|
| Animal Protocol |
In vivo animal studies typically employ mouse models of disease, such as LPS-induced endometritis. Animals are administered saikosaponin E via intraperitoneal or oral routes, followed by tissue collection for histopathological examination (H&E staining), MPO activity measurement, and cytokine analysis (TNF-α, IL-6) to evaluate anti-inflammatory and protective effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of saikosaponin E have been modeled computationally with a calculated LogP of 2.804, suggesting moderate membrane permeability. As a triterpenoid saponin glycoside with molecular weight 764.98 g/mol, it is expected to have limited oral bioavailability due to high molecular weight and poor permeability, typical of saponin compounds. DMSO solubility is 90 mg/mL.
|
| Toxicity/Toxicokinetics |
The cytotoxicity profile of saikosaponin E against human 293T cells (CC₅₀ = 2,850 nM) and cancer cell lines (IC₅₀ 15-21 μM) indicates moderate toxicity to mammalian cells. The selectivity index of 1.33 against influenza virus suggests a narrow therapeutic window. Further comprehensive toxicological studies are required.
|
| References | |
| Additional Infomation |
According to reports, Bupleurum chinense, Bupleurum falcatum, and other organisms with available data contain saikosaponin E.
Saikosaponin E is a natural product isolated from Bupleurum species (e.g., B. chinense, B. yinchowense) and is primarily used as a quality control marker and for mechanism-of-action studies in cancer and antiviral research. It shares structural homology with saikosaponin A and D but has a distinct β-OH substitution at C-16 contributing to its specific biological activities. No clinical trials or approved therapeutic indications have been identified for this compound. |
| Molecular Formula |
C42H68O12
|
|---|---|
| Molecular Weight |
764.9821
|
| Exact Mass |
764.471
|
| CAS # |
64340-44-9
|
| PubChem CID |
21637632
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.804
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
54
|
| Complexity |
1470
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]4([C@@H]3C=C[C@@]56[C@]4(C[C@@H]([C@@]7([C@H]5CC(CC7)(C)C)CO6)O)C)C)C)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O
|
| InChi Key |
KQGDHYQRJRGMDG-CYMACDCKSA-N
|
| InChi Code |
InChI=1S/C42H68O12/c1-21-28(45)33(54-34-31(48)30(47)29(46)22(19-43)52-34)32(49)35(51-21)53-27-11-12-38(6)23(37(27,4)5)9-13-39(7)24(38)10-14-42-25-17-36(2,3)15-16-41(25,20-50-42)26(44)18-40(39,42)8/h10,14,21-35,43-49H,9,11-13,15-20H2,1-8H3/t21-,22-,23+,24-,25-,26+,27+,28+,29-,30+,31-,32-,33+,34+,35+,38+,39-,40+,41-,42+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[[(1S,2S,4S,5R,8R,10S,13S,14R,17S,18R)-2-hydroxy-4,5,9,9,13,20,20-heptamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~130.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3072 mL | 6.5361 mL | 13.0722 mL | |
| 5 mM | 0.2614 mL | 1.3072 mL | 2.6144 mL | |
| 10 mM | 0.1307 mL | 0.6536 mL | 1.3072 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
